Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Enzyme Engineering. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN110592035B reveals high-efficiency carbonyl reductase mutants for chiral alcohol production, offering significant supply chain and cost advantages.
Patent CN102719500A details a continuous immobilized enzyme method for GABA. Offers high purity, green synthesis, and cost reduction for food additive manufacturing.
Patent CN115948360B reveals high-efficiency biocatalytic route for neurodegenerative drug intermediates with superior stereoselectivity and scalable production potential.
Novel PAMO enzyme technology enables green, one-step synthesis of esomeprazole with >99% ee, eliminating sulfone byproducts and reducing manufacturing costs for pharmaceutical supply chains.
Novel yeast-displayed lipase method for Vitamin E Linoleate production. Achieves higher conversion rates, reduces costs, and ensures scalable supply for pharmaceutical applications.
Novel esterase mutant enables high-yield chiral intermediate production. Reduces cost and improves supply chain reliability for pharmaceutical manufacturing.
Novel biocatalytic route for nicotine intermediate using engineered imine reductase mutants offering superior conversion and stereoselectivity for industrial scale-up.
Patent CN111944774B reveals novel MLADH enzyme for high-purity (R)-PED production. Offers significant cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN114703169A reveals a novel L-threonine aldolase mutant for Droxidopa. Achieves 92.89% selectivity. Ideal for pharma intermediates supply.
Patent CN106701723B details FSAA mutants for chiral synthesis. Offers cost reduction in chiral building block manufacturing with high stereoselectivity.
Discover the breakthrough recombinant dehydrogenase technology for L-glufosinate-ammonium production. Enhance supply chain reliability and reduce manufacturing costs with high-purity agrochemical intermediates.
Patent CN113088501A reveals a novel glutamate dehydrogenase mutant for L-glufosinate-ammonium production. Achieve ≥99% conversion and optical purity with reduced coenzyme costs.
Patent CN112941043B details a carbonyl reductase mutant for synthesizing chiral intermediates. Offers high yield and scalability for carbapenem antibiotic production supply chains.
Novel mutant enzyme method for PLP production ensures high purity and supply stability for global pharmaceutical and nutrition manufacturers seeking reliable partners.
Patent CN109456952B reveals a novel omega-transaminase mutant for Sitafloxacin intermediates. Discover cost-effective, scalable biocatalytic solutions for high-purity chiral amine production.
Patent CN116875575A reveals mutant enzyme for L-glufosinate. Achieves 99% conversion in 4h. Offers cost reduction and supply chain reliability for agrochemical manufacturing.
Patent CN102482648B details stereoselective reduction enhancing supply chain reliability and purity for pharmaceutical manufacturing.
Patent CN115975968B reveals novel amine dehydrogenase mutants for high-purity chiral amines. Offers significant cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Novel Yarrowia lipolytica enzyme method for PGF 2α production. Green synthesis ensures high purity and scalable supply chain solutions for global pharmaceutical intermediates manufacturing.
Patent CN115975969A discloses high-efficiency transaminase mutants for Sitagliptin synthesis, offering superior conversion rates and stability for cost reduction in API manufacturing.